Andrea Ellis, serving as a director at BridgeBio Pharma, Inc. (NASDAQ: BBIO), has reported the disposition of company common stock valued at $1,442,028. The transaction, which took place on July 9, 2026, involved the sale of 17,167 shares executed at a price of $84.00 per share. This insider activity occurs while BridgeBio's shares are trading at approximately $83.08, a level positioned close to the stock's 52-week high of $93.42. The recent price action reflects an impressive 85% return over the past year, according to market data.
According to analysis by InvestingPro, the current valuation of BridgeBio Pharma appears slightly overvalued relative to its calculated Fair Value. This assessment places the stock among considerations for lists highlighting potentially overvalued equities. Investors seeking comprehensive insights into BBIO and over 1,400 other US equities can access detailed Pro Research Reports.
The sale was executed pursuant to a Rule 10b5-1 sales plan that Ellis adopted on December 3, 2025. Prior to this sale, Ellis acquired 17,167 shares of BridgeBio Pharma common stock by exercising stock options. The exercise price for these options was set at $16.75 per share, resulting in a total value of $287,547. This acquisition was also conducted under the same Rule 10b5-1 plan.
The stock options exercised were part of a grant where one-third of the underlying shares vested on June 21, 2024, with an additional one-third vesting annually thereafter. Full vesting was achieved on June 21, 2026. Vesting is contingent on Ellis's continued service on the Board of Directors. These options carry an expiration date of June 21, 2033. Following these transactions, Andrea Ellis directly holds 22,579 shares of BridgeBio Pharma common stock and 17,167 shares underlying stock options.
In other corporate developments, BridgeBio Pharma has completed a significant $1 billion preferred equity investment. This transaction was led by funds managed by Sixth Street, with participation from HealthCare Royalty, a business of KKR. The investment involves Series A Cumulative Convertible Participating Preferred Stock, which carries a 7.00% initial dividend.
Market analysts have also adjusted their outlooks for the company. Mizuho lowered its price target for BridgeBio Pharma to $96 from $106, citing balance sheet concerns related to approximately $550 million in convertible notes due in 2027. Additionally, BridgeBio has announced new data on kidney function from its studies on acoramidis for transthyretin amyloid cardiomyopathy. The data shows an early, reversible dip in kidney function and a reduction in urinary albumin to creatinine ratio.
BridgeBio is also set to present data from a Phase 3 study of oral infigratinib in children with achondroplasia at the International Congress of Children’s Bone Health. The presentation will be delivered by Dr. Ravi Savarirayan of Murdoch Children’s Research Institute. Furthermore, Alnylam Pharmaceuticals and BridgeBio Pharma saw their shares rise following the failure of a rival drug by Ionis Pharmaceuticals in a late-stage trial. Both companies have approved drugs for the same disease, potentially benefiting from this outcome.
Recent market data shows BBIO trading at $83.08, down $2.81 or 3.27%, with after-hours trading at $84.00, up $0.92 or 1.11%. The stock's performance highlights ongoing advancements and challenges for BridgeBio Pharma as it navigates clinical trials, financing, and market valuation.